Purpose Temozolomide (TEM) based therapy has been reported being effective in the treatment of metastatic neuroendocrine neoplasms (NEN), with response rates ranging from 30 to 70%. Among patients affected by advanced glioblastoma or melanoma and treated with TEM, loss of tumoral O6-methylguanine DNA methyltransferase (MGMT) is correlated with improved survival. In NEN patients, the role of MGMT deficiency in predicting clinical outcomes of TEM treatment is still under debate. Methods In this study we evaluated 95 patients with advanced NENs undergoing treatment with TEM-based therapy. MGMT promoter methylation status was evaluated with two techniques: methylation specific-polymerase chain reaction or pyrosequencing. Results Treatment with TEM-based therapy was associated with an overall response rate of 27.4% according to RECIST criteria (51.8% of patients with and 17.7% without MGMT promoter methylation). Response to therapy, progression free survival and overall survival was correlated to MGMT status at univariate and multivariate analysis. Methylation of MGMT promoter could be a strong predictive factor of objective response and an important prognostic factor of a longer PFS and OS. Conclusion According to our results, MGMT methylation status, evaluated with methylation specific-polymerase chain reaction or pyrosequencing, should have an important role in patients with metastatic NENs, in order to guide therapeutic options. These results need further confirmation with prospective studies.
ORIGINAL ARTICLE
Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study Neuroendocrine neoplasms (NENs) are tumors arising from neuroendocrine cells. They are most frequently located in the lung, the pancreas and the gastrointestinal (GI) tract. Neuroendocrine tumors (NETs) have a reported incidence of 2.5-5 cases/100,000 people and a prevalence of 35/ 100,000 people [1] . NENs may be classified by grade (G)-G1 defined by mitotic index < 2 mitoses/10 high power fields (hpf) and Ki-67 ≤ 2%, G2 defined by mitotic index 2-20 mitoses/10 hpf and Ki-67 3-20%, and G3 defined by mitotic index > 20 mitoses/10 hpf and Ki-67 > 20% [2] . Another classification takes into account the expression of somatostatin receptors which can be targeted by somatostatin analogues (SSAs) and may represent a first line systemic treatment for stable or slowly progressive advanced disease. For those tumors not expressing somatostatin receptors and for those expressing them after progression to SSAs, the therapeutic landscape is rapidly evolving and multiple treatment options are currently available. Therefore, sequencing and tailoring the various available treatments is becoming more and more challenging. Randomized prospective studies reported the good clinical outcome of molecular therapies targeting angiogenesis and the mTOR pathway, such as sunitinib [3] and everolimus [4, 5] , in patients with advanced progressing NENs. Although targeted therapies are reported to frequently achieve prolonged progression-free survival (PFS) in patients with pNENs, they are rarely associated with objective tumor shrinkage [6] .
Response rates ranging from 30 to 70% are reported when TEM-based chemotherapy regimens are used in the treatment of metastatic pNENs [7] [8] [9] [10] . TEM is an oral alkylating agent, whose cytotoxic activity is related to DNA alkylation/methylation at the O6 and N7 positions of guanine, resulting in DNA mismatch and tumor cell death. The suicide enzyme O6-methylguanine DNA methyltransferase (MGMT) repairs DNA by removing the O6-alkylguanine adducts. High levels of MGMT, whose expression is regulated by mean of promoter methylation, contribute to chemoresistance by counteracting the therapeutic effect of alkylating agents [11] .
A loss of tumoral MGMT is associated with improved survival in patients affected by advanced glioblastoma or melanoma treated with TEM [12] [13] [14] . In NEN patients, however, conflicting results have been reported so far [15] [16] [17] [18] [19] [20] , and the role of MGMT deficiency in predicting the clinical outcome of patients treated with TEM is still under debate. The objective of our study was to evaluate retrospectively the value of MGMT status in predicting treatment efficacy in a large cohort of NEN-patients treated with TEM-based therapy.
Patients and methods

Study design and patients
A multicenter, international retrospective analysis of prospective institutional database was performed. The study included all consecutive patients with histologically proven, locally advanced or metastatic NENs treated with TEM, alone or in combination with capecitabine, in the participating centers (Sant'Orsola Malpighi Hospital, Bologna, Italy; Centre Hospitalier Universitaire de Lyon, Lyon, France; Istituto Nazionale dei Tumori, Milano, Italy; Policlinico di Modena, Modena, Italy) from January 2008 to March 2016. Inclusion criteria were: (a) histologically proven neuroendocrine neoplasms, (b) signed informed consent for participation in clinical research studies; (c) complete follow-up period in one of the participating institutions and (d) known MGMT promoter methylation status or availability of tissue material for sequencing. The primary end-point was to evaluate the correlation between objective response and MGMT promoter status. The secondary end-point was to evaluate the correlation between MGMT promoter status and both PFS and overall survival (OS).
At baseline evaluation, all patients underwent clinical examination, haematological, liver and kidney function tests, a computed tomography scan (CT) and/or magnetic resonance imaging (MRI). Patients received TEM alone or in combination with capecitabine (CAPTEM). TEM was administrated orally for five consecutive days every 28 days at dose set by investigator (not standardized). In the combination, capecitabine was administrated orally every 28 days at dose set by investigator (days 1-14) and TEM as described above (days [10] [11] [12] [13] [14] . All patients gave their informed written consent to the chemotherapy. The treatment was approved by the local Ethics Committee. Routine blood tests were performed before each cycle of therapy as well as during follow-up visits. The CT scan (or MRI) was repeated every 3 months (±1 month) until disease progression according to RECIST criteria (unless clinical conditions required shorter intervals).
Data analysis
All data were prospectively collected at the center where the patient had been enrolled. A single computerized data sheet was created and data regarding demographic, clinical and pathological features were retrospectively analysed. The histological specimens were examined by an experienced pathologist at each center. When required, an additional centralized revision of the tumor specimen was performed. Tumors were classified according to the 2010 WHO classification (gastro-entero-pancreatic neuroendocrine tumors) or 2004 WHO classification (thoracic neuroendocrine tumors) and the ENETS grading system [2, 21] . Ki-67 proliferation index was expressed as a percentage based on the count of Ki-67-positive cells in 2000 tumor cells in the areas of the highest immunostaining using the MIB1 antibody (DBA, Milan, Italy). The tumors were evaluated according to the RECIST criteria [22] . Objective response rate (ORR) was defined as the proportion of patients who achieved complete response (CR) or partial response (PR) as better response during therapy. Predictive factors for objective response were evaluated at univariate and multivariate analysis using logistic regression. Predictive factors were expressed as odds ratio (OR) [95 % confidence interval (CI)]. The multivariate model was designed using the forward stepwise method after including all variables. PFS was defined as the interval between the start of the therapy and the time of progression of disease (PD). PFS was measured using the Kaplan-Meier method and the results were compared using the log-rank test. Predictive risk factors for PD were evaluated by univariate and multivariate analysis using the Cox proportional hazards method. Risk factors were expressed as hazard ratios (HR) [95% confidence interval (CI)]. The multivariate model was designed using the forward stepwise method after including all variables. All analyses carried out for predictive and risk factors are listed in the tables. The distribution of the continuous variables was reported as median and interquartile range (IQR, 25th to 75th percentiles). The comparison between the subgroups was performed using Pearson's chisquare test (Fisher's exact test was used when appropriate) or the Mann-Whitney U test for continuous variables. The p value was considered significant when inferior to 0.05. Statistical analysis was performed using a dedicated software (IBM-SPSS Statistics v. 22).
MGMT promoter methylation
MGMT promoter methylation status was evaluated using two techniques: methylation specific-polymerase chain reaction (MS-PCR) or pyrosequencing (PSQ), obtaining, respectively, qualitative and quantitative information. All samples examined contained more than 80% tumor cells. DNA extraction from formalin-fixed, paraffin-embedded tissue was performed after deparaffinization using a purification kit (MasterPure DNA, Epicentre, Madison, WI, USA). Genomic DNA was modified by bisulfite conversion (EZ DNA Methylation Gold Kit, Zymo, Irvine, CA, USA). For MS-PCR, we used the primers and PCR conditions described by Dong et al. [23] .
Pyrosequencing was performed using the commercially available PyroMark Q24 CpG MGMT kit (Qiagen, Hilden, Germany) on a PyroMark Q24 System (Qiagen). Data were analyzed and quantified with the PyroMark Q24 Software 2.0.7 (Qiagen). The mean percentage of the five CpG methylated islands detected by the kit was used for analysis [24, 25] . For pyrosequencing analysis, an 8% cut off was used, accordingly to neuro-oncology clinical practice [25] . MGMT was considered methylated if methylated alleles were more than not methylated alleles by at least 8%; otherwise MGMT was scored as not methylated.
Results
Demographics and tumor characteristics
One hundred and four patients affected by NENs were enrolled at the participating centers. Nine patients were excluded at statistical analysis because TEM-based therapy was interrupted early (median: 2 cycles, range 1-3) without radiological evidence of progression (due to worsening of clinical conditions in five patients and to drug-related toxicity in four patients). The characteristics of the 95 patients are listed in Table 1 . There were 52 men and 43 women with a mean age of 62 years (range 20-84 years). In 43 of the 95 patients (45.3%), the primary lesion was located in the pancreas, in 22 (23.2%) it was in the lung, whereas in 30 (31.6%) it was in: GI tract (21 patients), larynx (1 patient), unknown (6 patients) or adrenal gland (2 patients). According to the 2010 WHO classification, 7 
Treatment outcome
Patients received a median of six cycles of chemotherapy (range 1-45). Reasons for treatment discontinuation included radiological tumor progression (n = 48), maximal response or chemotherapy break (at physician's discretion; n = 38), unacceptable toxicity (n = 1) and patient decision (n = 1). Seven patients were still on treatment at the time of data analysis. All 95 patients were assessable for radiographic response. When best response to therapy was evaluated, 26 (27.4%) patients experienced PR according to RECIST criteria, whereas 42 (44.2%) had stable disease and 27 (28.4%) experienced PD. Fourteen patients MGMT+ (51.8%) and 12 patients MGMT− promoter methylation (17.7%; p = 0.001) achieved an objective response ( Table 1) . As reported in Table 2 
Progression-free survival
At the time of data cut-off, 74 patients (77.9%) had PD. Median PFS was 10 months (95% CI: 5.6-14.4 months; Fig. 1 ). Significant differences in PFS were observed according to MGMT promoter methylation with median PFS being 21 and 8 months for MGMT+ and MGMT−, respectively (p = 0.017, Fig. 2 ). Differences in PFS were also correlated with previous chemotherapy (yes/no: 6/ 17 months, p = 0.039) and objective response during treatment (median PFS: 27 vs. 7 months; p = 0.001); however, no statistically significant difference was observed when correlating PFS to sex (median in male: 11 months, female: 9 months; p = 0.881), grading (median in high grade: 9 months, low grade: 12 months; p = 0.309), primary site (median in pancreas: 13 months, lung: 12 months, other: 7 months; p = 0.212), regimen (median in CAPTEM: 13 months, TEM: 7 months, p = 0.758) and line of therapy (median in first line: 17 months, not first line: 9 months, p = 0.336).
Risk factors for PFS were reported in Table 3 . At univariate analysis, significant risk factors were MGMT-(HR: 1.88, p = 0.023), higher Ki67 (HR: 1.01, p = 0.029) and previous chemotherapy (HR: 1.60, p = 0.048). These risk factors, previously identified at univariate analysis, were also confirmed at multivariate 
Discussion
In this series, we have evaluated retrospectively the predictive value of MGMT methylation status by MS-PCR or PSQ in a large cohort of NEN patients treated with TEM-based chemotherapy. We observed that MGMT promoter methylation was a strong predictive factor for objective response and an important prognostic factor of longer PFS and OS.
It has been widely reported that MGMT status is a powerful predictor of response to TEM for newly diagnosed glioblastoma patients [26] . MGMT status is commonly assessed by immunohistochemistry (IHC), MS-PCR, quantitative MS-PCR (qMS-PCR), and/or PSQ. Immunohistochemistry stain for MGMT protein expression was the easiest method to perform, but it had a lower predictive power for PFS and OS. On the contrary, PSQ, MS-PCR, and qMS-PCR represent the gold standard methods to evaluate MGMT status [27] . In the last 10 years, evidences suggesting the efficacy of TEM in metastatic NENs are mounting [7-10, 15, 18, 19] . Therefore, the use of TEM, either as mono-or combination therapy with capecitabine, has been reported for the first time in the most recently updated ENETS guidelines [28] . Nevertheless, previous studies concerning the role of MGMT status in NENs reported contrasting results. In two previous studies [15, 19, [29] [30] [31] no correlation was found between MGMT status and response to TEM. In three other studies [16, 18, 20] , a predictive value was found only in the sub-group of pancreatic NENs. In all these series, the evaluation of MGMT status was observed in a scarce number of cases and only in three series MS-PCR or PSQ techniques were used [18, 29, 30] .
The primary end-point of our study was the identification of a correlation between MGMT promoter methylation [17] . On the other hand, Cives et al. in 2016 reported a ORR of 54% in a large cohort of pancreatic NENs [19] . Our data was similar to what reported by Walter and, if considering only pancreatic NENs, we found a lower ORR (34%) compared to the data reported by Cives. These differences could be explained considering the different therapeutic approaches used. In fact, Cives reported the use of a specific CAPTEM schedule while we used TEM alone (31.9% of pancreatic NENs) or associated with capecitabine (68.1% of pancreatic NENs) in different and not standardized schedules.
Considering the secondary end-point, in our series we observed a significant difference in PFS after TEM-based therapy according to MGMT status. Median PFS was found to be significantly longer in patients with MGMT promoter methylation (21.0 vs. 8.0, p = 0.017). The analysis of prognostic factors for disease progression showed that the absence of MGMT promoter methylation increased the risk of disease progression 2.5 times at multivariate analysis. Our data were similar to those published by Walter et al, reporting a 16 months' difference in median PFS between methylated and not methylated patients (26.0 vs. 10.8 months) [17] . Recently, Raj et al. did not report any correlation with MGMT status nor response to alkylating agent therapy in a cohort of 46 patients with pancreatic NETs [30] . In this paper, PSQ was performed only in 28/56 patients and only a descriptive statistics analysis is reported.
In our series, a higher Ki67 value and previous chemotherapy represented another independent prognostic factors of disease progression. The role of Ki67 as a prognostic factor in NENs is well known and widely demonstrated [32] [33] [34] . No differences were found when considering the primary site and the association between capecitabine and TEM.
Overall survival with TEM-based therapy was significantly longer in patients with MGMT promoter methylation (not reached vs. 23 months, p = 0.057) and MGMT status, Ki67 and previous chemotherapy were prognostic factors for death at multivariate analysis. Walter et al. described similar result in 2015 with a median OS of 77 and 43 months in patients with and without MGMT promoter methylation [17] . Our results confirmed the role of MGMT status in OS in a larger cohort of patients treated with TEMbased therapy.
However, our results must be interpreted with some caution due to the retrospective design of our study, due to the use of two different technical methods to evaluate MGMT status (PSQ and MS-PCR) and to the fact that TEMbased therapy has been used with different schedules, making it difficult to properly assess its role in treatment efficacy. Prospective studies based on the assessment of MGMT status which could confirm our results are ongoing: an Italian phase II study testing TEM and lanreotide in bronchial carcinoid tumors (ClinicalTrials.gov Identifier: NCT02698410) and an American randomized phase II study comparing TEM-capecitabine vs. TEM alone in pancreatic NET (ClinicalTrials.gov Identifier: NCT01824875).
In conclusion, our data suggests a role of MGMT status, evaluated with MS-PCR or PSQ, in patients treated with TEM-based therapy. Methylation of MGMT promoter could be considered a predictive factor for objective response and a prognostic factor for a longer PFS and OS. Prospective studies to confirm this evidence are required but, currently, the status of MGMT should have an important role in the decision making for patients with metastatic NENs, in order to plan the best therapeutic approach.
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